# Post Marketing Surveillance Study to Evaluate the Tolerability of Rebif® New Formulation in Patients With Relapsing Multiple Sclerosis in an Australian Clinical Setting.

> **NCT01101776** · — · COMPLETED · sponsor: **Merck KGaA, Darmstadt, Germany** · enrollment: 49 (actual)

## Conditions studied

- Multiple Sclerosis

## Interventions

- **DRUG:** Interferon beta-1a (Rebif)

## Key facts

- **NCT ID:** NCT01101776
- **Lead sponsor:** Merck KGaA, Darmstadt, Germany
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2010-01
- **Primary completion:** 2013-04
- **Final completion:** 2013-04
- **Target enrollment:** 49 (ACTUAL)
- **Last updated:** 2014-08-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01101776

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01101776, "Post Marketing Surveillance Study to Evaluate the Tolerability of Rebif® New Formulation in Patients With Relapsing Multiple Sclerosis in an Australian Clinical Setting.". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01101776. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*